Tenderwize
Zurück zur Suche

Open-house rebate agreement for Tiaprid

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Dec 03, 2027 · 462 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tiaprid, ATC N05AL03

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

62 / 100

Komplexität

58 / 100

Risikofaktoren

The notice explicitly says the contract documents must be submitted via the communication area in the DTVP portal and n...

Only pharmaceutical companies are eligible as potential contract partners, and a signed declaration of reliability is r...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Non-exclusive open-house rebate agreements for the medicinal product Tiaprid, ATC N05AL03.
  • Supply contract for pharmaceutical products.
Vollständige Zusammenfassung anzeigen

This is an open-house pharmaceutical supply arrangement for Tiaprid (ATC N05AL03) led by AOK Bayern. It is not a competitive open procedure in substance: the notice states that all interested pharmaceutical companies meeting the stated suitability requirement may join on identical, non-negotiable terms. The contract period runs from 2026-02-01 to 2028-01-31, with contract entry possible until 2027-12-03. Submission is via DTVP electronic channel with a qualified electronic signature, or by signed paper originals in duplicate. No contract value is stated.

Risiken

The notice explicitly says the contract documents must be submitted via the communication area in the DTVP portal and n...

Only pharmaceutical companies are eligible as potential contract partners, and a signed declaration of reliability is r...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submit the signed contract, the completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and the signed declaration of reliability.
  • The declaration of reliability must be signed and submitted with the tender documents.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate agreement for Tiaprid

Open-house non-exclusive pharmaceutical rebate agreement for Tiaprid (ATC N05AL03). Scope is supply of pharmaceutical products under a pre-set contract; the notice says the contract terms are identical and not individually negotiable. Place of performance is Germany, region DE212 (Bavaria/Munich area as indicated by buyer address and lot data).

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Jan 2026 - Jan 2028

Kategorie

Pharmaceutical products

Frist

Deadline Dec 03, 2027

Vergabedetails

Veröffentlichungsdatum
14 Dec 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
831717-2025

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30